FDA Approves Actos ANDA Before Exclusivity Expires; Shared 180-Day Awards At Risk?
Executive Summary
Ranbaxy waived its right to 180-day exclusivity for generic Actos with respect to Macleods’ ANDA, but whether FDA would allow the same for post-MMA applications remains an open question.